Literature DB >> 24317127

Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.

L Farina1, A Guidetti2, F Spina1, L Roncari1, P Longoni1, F Ravagnani3, C Carlo-Stella4, P Corradini5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24317127     DOI： 10.1038/bmt.2013.193

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  16 in total

1.  Enumeration of CD34+ cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy.

Authors:  A M Brocklebank; R L Sparrow
Journal:  Cytometry       Date:  2001-08-15

2.  Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

Authors:  Corrado Tarella; Roberto Passera; Michele Magni; Fabio Benedetti; Andrea Rossi; Angela Gueli; Caterina Patti; Guido Parvis; Fabio Ciceri; Andrea Gallamini; Sergio Cortelazzo; Valerio Zoli; Paolo Corradini; Alessandra Carobbio; Antonino Mulé; Marco Bosa; Anna Barbui; Massimo Di Nicola; Marco Sorio; Daniele Caracciolo; Alessandro M Gianni; Alessandro Rambaldi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

Authors:  I Ricca; M Compagno; M Ladetto; A Rocci; M Dell'Aquila; P Omedè; F De Marco; S D'Antico; D Caracciolo; D Ferrero; C Carlo-Stella; C Tarella
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

4.  Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.

Authors:  Lucia Farina; Francesco Spina; Anna Guidetti; Paolo Longoni; Fernando Ravagnani; Anna Dodero; Vittorio Montefusco; Carmelo Carlo-Stella; Paolo Corradini
Journal:  Leuk Lymphoma       Date:  2013-06-14

5.  Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.

Authors:  Esa Jantunen; Taru Kuittinen; Eija Mahlamäki; Marja Pyörälä; Pentti Mäntymaa; Tapio Nousiainen
Journal:  Eur J Haematol       Date:  2011-01-31       Impact factor: 2.997

6.  Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

Authors:  Immacolata Attolico; Vincenzo Pavone; Angelo Ostuni; Bernardo Rossini; Maurizio Musso; Alessandra Crescimanno; Massimo Martino; Pasquale Iacopino; Giuseppe Milone; Patrizia Tedeschi; Sabrina Coluzzi; Roberta Nuccorini; Sara Pascale; Elvira Di Nardo; Attilio Olivieri
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-24       Impact factor: 5.742

7.  Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

Authors:  R F Duarte; B E Shaw; P Marín; P Kottaridis; M Ortiz; C Morante; J Delgado; J Gayoso; R Goterriz; C Martínez-Chamorro; J J Mateos-Mazón; C Ramírez; J de la Rubia; H Achtereekte; P J Gandhi; K W Douglas; N H Russell
Journal:  Bone Marrow Transplant       Date:  2010-03-22       Impact factor: 5.483

8.  AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Authors:  G Calandra; J McCarty; J McGuirk; G Tricot; S-A Crocker; K Badel; B Grove; A Dye; G Bridger
Journal:  Bone Marrow Transplant       Date:  2007-11-12       Impact factor: 5.483

9.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

Authors:  Florent Malard; Nicolaus Kröger; Ian H Gabriel; Kai Hübel; Jane F Apperley; Grzegorz W Basak; Kenneth W Douglas; Catarina Geraldes; Ozren Jaksic; Zdenek Koristek; Francesco Lanza; Roberto Lemoli; Gabor Mikala; Dominik Selleslag; Nina Worel; Mohamad Mohty; Rafael F Duarte
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-13       Impact factor: 5.742
View more
  1 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.